Friday, December 15, 2023 2:53:27 PM
manibiotech,
One thing even you must acknowledge and that is that Sawston represents a scalable model for manufacturing once Edens is fully validated and who needs a sales force when every cancer patient in the world is going to want this treatment for their cancer. At that point money comes from everywhere willing to help with the buildout and skilled labor and leadership coming from those most impacted will not be in short supply. As far as additional research, NWBO has contacts with the best in the world and their SAB will be considered second to none.
I believe Linda has a transition plan which may include a partner but she is full of surprises and just like Laura Posner obviously reminds me of a younger Linda, I’m certain Linda has a few folks in mind for any and all contemplated next steps.
Don’t think for a minute that she won’t wait for the true value of Direct and proteomics data to materialize before handing over the keys. Best wishes.
One thing even you must acknowledge and that is that Sawston represents a scalable model for manufacturing once Edens is fully validated and who needs a sales force when every cancer patient in the world is going to want this treatment for their cancer. At that point money comes from everywhere willing to help with the buildout and skilled labor and leadership coming from those most impacted will not be in short supply. As far as additional research, NWBO has contacts with the best in the world and their SAB will be considered second to none.
I believe Linda has a transition plan which may include a partner but she is full of surprises and just like Laura Posner obviously reminds me of a younger Linda, I’m certain Linda has a few folks in mind for any and all contemplated next steps.
Don’t think for a minute that she won’t wait for the true value of Direct and proteomics data to materialize before handing over the keys. Best wishes.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
